Panelists discuss how incorporating subcutaneous (SubQ) formulations into clinical formularies requires careful evaluation of clinical equivalence, workflow fit, and reimbursement logistics, with ...

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way anti-cancer immunotherapy is administered from intravenous administration to ...

When deciding whether to use subcutaneous (SubQ) or intravenous (IV) therapies, clinicians must weigh several clinical and practical factors. One of the first considerations is the type of cancer ...

CHICAGO — Administering the bispecific antibody amivantamab (Rybrevant) subcutaneously rather than intravenously in combination with lazertinib (Leclaza) not only reduces administration times but also ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

Lundbeck has stopped development of a subcutaneous formulation of its migraine drug Lu AG09222 as the Danish drugmaker switches its focus to intravenous delivery after seeing phase 2b data, delaying ...